Screener
Syndax Pharmaceuticals SNDX Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026. Open the filing →
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
FAQ
- What is Syndax Pharmaceuticals's shares (diluted)?
- Syndax Pharmaceuticals (SNDX) reported shares (diluted) of 88.3M in Q1 2026.
- How has Syndax Pharmaceuticals's shares (diluted) changed year-over-year?
- Syndax Pharmaceuticals's shares (diluted) increased by 2.4% year-over-year, from 86.2M to 88.3M.
- What is the long-term trend for Syndax Pharmaceuticals's shares (diluted)?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's shares (diluted) has grown at a 13.5% compound annual growth rate (CAGR), from 208.7M to 345.8M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Syndax Pharmaceuticals's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude